CTOR Quote, Financials, Valuation and Earnings

Citius Pharmaceuticals has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Citius Pharmaceuticals's return on equity of --.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 364.4%. On the other hand Citius Pharmaceuticals has an analysts' consensus of $5.67 which suggests that it could grow by 472.97%. Given that Citius Pharmaceuticals has higher upside potential than Citius Oncology, analysts believe Citius Pharmaceuticals is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Citius Pharmaceuticals has a beta of 1.189, suggesting its more volatile than the S&P 500 by 18.941%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Citius Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Citius Pharmaceuticals pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Citius Pharmaceuticals quarterly revenues of --. Citius Oncology's net income of -$6.7M is higher than Citius Pharmaceuticals's net income of -$9.8M. Notably, Citius Oncology's price-to-earnings ratio is -- while Citius Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus -- for Citius Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to Citius Oncology's net margin of -49.65%. Citius Oncology's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 364.4%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that Citius Oncology has higher upside potential than NovaBay Pharmaceuticals, analysts believe Citius Oncology is more attractive than NovaBay Pharmaceuticals.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Citius Oncology's net income of -$6.7M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Citius Oncology's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to Citius Oncology's net margin of --. Citius Oncology's return on equity of -- beat Palatin Technologies's return on equity of --.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 364.4%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than Citius Oncology, analysts believe Palatin Technologies is more attractive than Citius Oncology.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of --. Citius Oncology's net income of -$6.7M is higher than Palatin Technologies's net income of --. Notably, Citius Oncology's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to Citius Oncology's net margin of -18.58%. Citius Oncology's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

Citius Oncology has a consensus price target of $3.00, signalling upside risk potential of 364.4%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Citius Oncology has higher upside potential than Retractable Technologies, analysts believe Citius Oncology is more attractive than Retractable Technologies.

Citius Oncology has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

Citius Oncology has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Citius Oncology pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

Citius Oncology quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. Citius Oncology's net income of -$6.7M is lower than Retractable Technologies's net income of -$1.9M. Notably, Citius Oncology's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Citius Oncology is -- versus 0.63x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.